e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Prognostic factors and subtyping of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
E. Trigka, G. Hardavella, A. Saetta, N. Kavantzas, P. Korkolopoulou, N. Anastasiou, E. Patsouris (Athens, Greece)
Source:
Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Session:
Prognostic factors and subtyping of lung cancer
Session type:
Thematic Poster Session
Number:
2923
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Trigka, G. Hardavella, A. Saetta, N. Kavantzas, P. Korkolopoulou, N. Anastasiou, E. Patsouris (Athens, Greece). A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Eur Respir J 2013; 42: Suppl. 57, 2923
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Challenges in the management of SCLC
Related content which might interest you:
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
SMYD3 links lysine methylation of MAP3K2 to ras-driven lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Correlation of bim and noxa expression with clinicopathological features in NSCLC
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Correlation of miR-422a, miR-21 and miR-155 analysis with hMSH2 and hMLH1 mRNA expression profiles in non-small cell lung carcinomas and their adjacent normal tissues
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Correlation between EGFR mutations and emphysematous changes in heavy smokers with lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept